ライフサイエンスコーパス: vinblastine

1 levels of intracellular drug (paclitaxel and vinblastine).

2 terface when compared to the parent compound vinblastine.

3 bule structure by imaging in the presence of vinblastine.

4 nced cell death in vitro in combination with vinblastine.

5 peutic spindle poisons such as paclitaxel or vinblastine.

6 to paclitaxel, docetaxel, epothilone B, and vinblastine.

7 rupting their transport on microtubules with vinblastine.

8 PC-6827, paclitaxel, and colchicine, but not vinblastine.

9 essing breast cancer cells to paclitaxel and vinblastine.

10 mpete with [(3)H]paclitaxel (Taxol) or [(3)H]vinblastine.

11 eatment with the microtubule-modifying agent vinblastine.

12 ylation in KB-3 carcinoma cells treated with vinblastine.

13 rotubule dynamics with low doses of taxol or vinblastine.

14 uding the chemotherapeutics, vincristine and vinblastine.

15 We induced leukopenia in guinea pigs with vinblastine (0.7 mg/kg, intravenously, 4 days before) an

16 1 to 4, dacarbazine 800 mg/m2 on day 1 only, vinblastine 1.6 mg/m2 on days 1 to 4, interleukin-2 tota

17 paclitaxel (originally called taxol; 1 muM), vinblastine (1 and 10 muM), colchicine (10 and 100 muM),

18 A series of 180 vinblastine 20' amides were prepared in three steps from

19 methotrexate 30 mg/m(2) days 1, 15, and 22, vinblastine 3 mg/m(2) days 2, 15, and 22, doxorubicin 30

20 clitaxel (3-fold), vincristine (3-fold), and vinblastine (3-4-fold).

21 ids, including vincristine, vinorelbine, and vinblastine (4.29- to 6.40-fold), but minimal resistance

22 intermediate iminium ion directly providing vinblastine (40-43%) and leurosidine (20-23%), its natur

23 C (10 mg/m(2) day 1 and every 28 days) plus vinblastine (5 mg/m(2) day 1, day 14, day 28, and day 42

24 year or to an intravenous regimen combining vinblastine (5 mg/m(2) per dose) and methotrexate (30 mg

25 received 6 cycles of doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000

26 plus MVP (four cycles of mitomycin 6 mg/m2, vinblastine 6 mg/m2, and cisplatin 50 mg/m2 every 3 week

27 Vinblastine (6 mg/m(2)) was administered weekly for 1 ye

28 e MTAs paclitaxel, an assembly promoter, and vinblastine, a disassembly promoter.

29 For example, vinblastine, a prototypic drug of this class, induced th

30 the amount of intracellular accumulation of vinblastine, a surrogate marker for the activity of P-gp

31 g radiation, a double-strand break agent, or vinblastine, a tubulin poison.

32 : destabilizing MTAs, such as colchicine and vinblastine, accelerate aging in an EB-dependent manner,

33 compound enhancing 50% of the intracellular vinblastine accumulation in the KB/MDR cells) and 3 time

34 mes higher, based on Amax (the intracellular vinblastine accumulation of the KB/MDR cells caused by t

35 Cytochalasin D and vinblastine, actin and microtubule inhibitors, respectiv

36 Conclusion Vinblastine administered once per week is well tolerated

37 ients treated with neoadjuvant methotrexate, vinblastine, Adriamycin (doxorubicin), and cisplatin, th

38 Vinblastine also promoted Bax activation and Bax oligome

39 r the preparation of previously inaccessible vinblastine analogs and define powerful new methodology

40 difications at C6-C8, were incorporated into vinblastine analogues and used to probe the unusual impo

41 he total synthesis of a systematic series of vinblastine analogues that contain deep-seated structura

42 er cell line, and an important subset of the vinblastine analogues that display little or no differen

43 nit followed by their incorporation into the vinblastine analogues through the use of a single-step b

44 situ oxidation to provide the corresponding vinblastine analogues, their evaluation provided unantic

45 ubstituents, remarkably enhancing potency of vinblastine analogues.

46 ed by CPT are not observed with cisplatin or vinblastine and are not simply due to reduced Top1 activ

47 re commonly displayed resistance to combined vinblastine and corticosteroid therapy (21.9% v 3.3%; P

48 rial movement in astrocytes was inhibited by vinblastine and cytochalasin D, demonstrating that this

49 To reduce doxorubicin, bleomycin, vinblastine and dacarbazine toxicity, the Cancer and Leu

50 es received standard doxorubicin, bleomycin, vinblastine and dacarbazone (ABVD) therapy since Jan 1,

51 ve inhibitors of the binding of radiolabeled vinblastine and dolastatin 10 to tubulin.

52 etoconazole and doxorubicin alternating with vinblastine and estramustine before emergence of a castr

53 etoconazole and doxorubicin alternating with vinblastine and estramustine, given in addition to stand

54 nts in other chemotherapeutic classes (e.g., vinblastine and etoposide) also increased with the mutat

55 Vinblastine and other microtubule inhibitors used as ant

56 The role of single-agent vinblastine and other vinca alkaloid in the management o

57 ulted in a marked increase in sensitivity to vinblastine and paclitaxel, drugs that are known to be m

58 orubicin and greatly enhanced sensitivity to vinblastine and paclitaxel.

59 se nicely on the tubulin-bound structures of vinblastine and phomopsin A.

60 sensitivity of drug-resistant Leishmania to vinblastine and rhodamine 123.

61 sed at 6 mg/kg i.v. with an anticancer drug, vinblastine and shown is the distribution of the precurs

62 Vinblastine and vincristine are condensed from the monot

63 Antitumor substances related to vinblastine and vincristine are exclusively found in the

64 e noncompetitively inhibiting the binding of vinblastine and vincristine to beta-tubulin.

65 nthetic precursor for the anti-cancer agents vinblastine and vincristine, as well as other biological

66 ) is the sole source of the anticancer drugs vinblastine and vincristine, bisindole alkaloids derived

67 lkaloids, including the low-level anticancer vinblastine and vincristine, for which the late biosynth

68 wn for producing bioactive compounds such as vinblastine and vincristine, which are classified as ter

69 ir dimeric terpenoid indole alkaloids (TIAs) vinblastine and vincristine, which are used in cancer ch

70 the clinically significant anticancer agents vinblastine and vincristine.

71 the potent, expensive anti-cancer compounds vinblastine and vincristine.

72 e alkaloids, including the anti-cancer drugs vinblastine and vincristine.

73 alkaloids, among which the anti-cancer drugs vinblastine and vincristine.

74 orubicin, 10 units/m(2) bleomycin, 6 mg/m(2) vinblastine, and 375 mg/m(2) dacarbazine) or AVD (ABVD m

75 alue 3 times lower than the positive control vinblastine, and against human breast cancer cell lines

76 ycles of PE plus three cycles of ifosfamide, vinblastine, and bleomycin.

77 , epidoxorubicin, vincristine, procarbazine, vinblastine, and bleomycin; CEC) in patients with advanc

78 mbination regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (19%), or other regimens (1

79 ma to treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone or to treatmen

80 roup trial comparing doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and Stanford V regim

81 wo initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2

82 to eight courses of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) despite more adverse

83 thotrexate (VBM), or doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in C studies; and Vb

84 after two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in previously untrea

85 ma (HL) treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in the HAART era acc

86 of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy

87 atients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) were enrolled retros

88 s Lymphoma) compared doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with mechlorethamine

89 Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without radi

90 he majority received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-like chemotherapy.

91 classic combination doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

92 received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

93 and was recently approved with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untrea

94 were randomly assigned to receive cisplatin, vinblastine, and dacarbazine (CVD) either alone or concu

95 rapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed

96 motherapy regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (or equivalent).

97 nation with standard doxorubicin, bleomycin, vinblastine, and dacarbazine (RABVD) in patients with cl

98 by widespread use of doxorubicin, bleomycin, vinblastine, and dacarbazine and diminishing use of radi

99 Increasing age, doxorubicin, bleomycin, vinblastine, and dacarbazine as initial therapy, and gra

100 5) received a fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field ra

101 t with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine followed by RT is rare.

102 ed with a regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin disease (HD) an

103 four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field r

104 (CMT) with 2x ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiothera

105 two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) as compared with standard

106 ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded a

107 two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy, and then und

108 rentuximab vedotin (BV) and AVD (adriamycin, vinblastine, and dacarbazine) followed by 30 Gy involved

109 Although ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) has been established as th

110 r standard ABVD (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) therapy.

111 ed 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) with IFRT.

112 six cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), four escalated plus two s

113 umbers and follow-up, adriamycin, bleomycin, vinblastine, and dacarbazine.

114 fter three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients

115 EACOPP compared with doxorubicin, bleomycin, vinblastine, and dacarbazine; cyclophosphamide, vincrist

116 lating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vin

117 rbazine, prednisone, doxorubicin, bleomycin, vinblastine, and dacarbazine; or standard BEACOPP (P = .

118 B conducted a phase 2 trial of doxorubicin, vinblastine, and gemcitabine for newly diagnosed, nonbul

119 such as calcein-AM, bodipy-verapamil, bodipy-vinblastine, and mitoxantrone.

120 crotubule disruptive drugs such as colcemid, vinblastine, and nocodazole.

121 7 were notably more potent than vinorelbine, vinblastine, and paclitaxel in the NCI/ADR-RES and Messa

122 ine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone).

123 many other substrates (including verapamil, vinblastine, and rifampicin) of the well studied multidr

124 nd T-cell lymphoma) resistant to paclitaxel, vinblastine, and teniposide.

125 uppresses on-off kinetics, characteristic of vinblastine, and the other a "pseudo" kinetic stabilizat

126 vide a unique entry into C20' functionalized vinblastines, and afford initial insights into the obser

127 interdimer interface so that it contacts the vinblastine- and dolastatin 10-binding sites believed to

128 g of catharanthine with vindoline to provide vinblastine are described along with key mechanistic and

129 reased resistance of PC-3 cells to Taxol and vinblastine, as assessed by viability and clonogenic sur

130 The BODIPY FL-vinblastine-based biochemical assay is suitable for high

131 We describe a BODIPY FL-vinblastine-based human PXR time-resolved fluorescence r

132 nd colchicinoid molecules and a single bound vinblastine between the two heterodimers (Nature (Lond)

133 ompound is shown to not significantly affect vinblastine binding to tubulin; however, experiments sug

134 mbly by binding at either the colchicine- or vinblastine-binding site.

135 vinblastine (PAVe) in S studies; MOPP, PAVe, vinblastine, bleomycin, and methotrexate (VBM), or doxor

136 However, neither taxol nor vinblastine, both of which block microtubule dynamics wh

137 fers resistance to hydrophobic drugs such as vinblastine, but increases the sensitivity of these para

138 ivatives that match or exceed the potency of vinblastine by as much as 10-fold in cell-based function

139 of the tubulin binding site surrounding the vinblastine C20' center depicted in an X-ray cocrystal s

140 Both 10 mm colchicine and 0.1 mm vinblastine caused AMS to develop in 30.6% and 33.3% of

141 3-null cells but not in p53 wild-type cells, vinblastine caused down-regulation of p21 expression con

142 of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) chemotherapy in patients with muscle-i

143 Treatment of both types of cells with vinblastine, colchicine, or nocodazole reversed alpha-sy

144 Dose escalation of a folate-targeted vinblastine compound, EC0905, was conducted in dogs with

145 ation of mitosis in nocodazole, colcemid, or vinblastine concentrations that inhibit MT assembly vari

146 571 sensitizes embryos to the toxic compound vinblastine, confirming that one role for the efflux tra

147 r activity and toxicity of a folate-targeted vinblastine conjugate were evaluated in dogs with natura

148 a liposomal delivery system for a prodrug of vinblastine (CPD100) which converts to the parent compou

149 clitaxel for binding to tubulin but not with vinblastine, crocin, or colchicine; and 6) leads to micr

150 mized to 6 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) alone or 6 cycles of ABV

151 ity of two cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-fiel

152 ng after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) to guide treatment modif

153 eceived doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine chemotherapy along with involve

154 inister the standard doxorubicin, bleomycin, vinblastine, dacarbazine chemotherapy regimen, prescribe

155 n of rituximab-ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for stage II-IV untreated clas

156 herapy induction regimen included cisplatin, vinblastine, dacarbazine, decrescendo interleukin-2 (IL-

157 nced progression on or after BCT (cisplatin, vinblastine, dacarbazine, IL-2 9 MU/m(2)/d for 4 days, a

158 ing adjuvant biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 (IL-2), and inte

159 at baseline and after 2 adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) courses with (18)F-FDG PE

160 0-fold) and define the potential role of the vinblastine Delta(6,7)-double bond.

161 otal synthesis of a systematic series of key vinblastine derivatives is detailed and used to characte

162 ently resistant to neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy, and

163 les of neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) would be

164 cer, treatment with dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) results

165 e for benefit from combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) adjuvant

166 patients received neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemother

167 basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topote

168 ical outcome after neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC).

169 bine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [high-dose MVAC]

170 Methotrexate, vinblastine, doxorubicin, and cisplatin and gemcitabine

171 upports the use of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by cyst

172 instays of chemotherapy remain methotrexate, vinblastine, doxorubicin, and cisplatin, and gemcitabine

173 with low-risk Hodgkin's disease treated with vinblastine, doxorubicin, methotrexate, and prednisone (

174 Patients received CMT with chemotherapy (vinblastine, doxorubicin, methotrexate, and prednisone [

175 ganglioside levels, restored sensitivity to vinblastine, enhanced vinblastine uptake 3-fold, and dim

176 , cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate t

177 and resistance to treatments with TNFalpha, vinblastine, etoposide and gamma-radiation.

178 hamine, doxorubicin, vincristine, bleomycin, vinblastine, etoposide, and prednisone (Stanford V).

179 ubicin, methotrexate, and prednisone [VAMP]; vinblastine, etoposide, prednisone, and doxorubicin; or

180 o better regulate the biodistribution of the vinblastine-folate conjugate, EC145, a new folate-spacer

181 and MS/MS imaging experiments by separating vinblastine from an endogenous isobaric lipid.

182 we report the characterization of BODIPY FL-vinblastine, generated by labeling vinblastine with the

183 ib group and 20 patients in the methotrexate-vinblastine group were assessable for activity.

184 diarrhoea (n=7, 15%) and in the methotrexate-vinblastine group were neutropenia (n=10, 45%) and liver

185 he pazopanib group; n=24 in the methotrexate-vinblastine group).

186 d and six patients (27%) in the methotrexate-vinblastine group.

187 noterpene precursor of the anti-cancer agent vinblastine, has remained largely unexplored.

188 Many natural products, including vinblastine, have not been easily subjected to simplific

189 tine that matched or exceeded the potency of vinblastine in cell growth inhibition assays.

190 ability to promote uptake of calcein AM and vinblastine in multidrug-resistant cells.

191 ability to promote uptake of calcein AM and vinblastine in multidrug-resistant MDCKII-MDR1 cells, an

192 motherapeutic agents such as doxorubicin and vinblastine in NSCLC.

193 of this study was to assess the activity of vinblastine in therapy-naive children.

194 hetically derived, structurally more complex vinblastines inaccessible from the natural product itsel

195 ncubation of microtubules with 2 or 4 microM vinblastine induced additional lower-affinity eribulin b

196 oposide and cisplatin nor the tubulin-binder vinblastine induced enhanced levels of radiosensitizatio

197 Vinblastine induced the translocation of Bax from the cy

198 uding epothilone B analogue (BMS-247550) and vinblastine, induced apoptosis of Bax-positive HCT116 ce

199 The results indicate that vinblastine-induced apoptosis requires translocation, ac

200 Overexpression of Bcl-xL inhibited vinblastine-induced Bax activation and Bax dimerization

201 ription and protein translation blocked both vinblastine-induced c-Jun expression and apoptotic cell

202 d was found to be highly effective, reducing vinblastine-induced c-Jun expression at both the mRNA an

203 in protein level or nuclear localization of vinblastine-induced c-Jun, or of one of its target genes

204 Lipopolysaccharide-challenged, vinblastine-induced leukopenic guinea pigs exhibit hyper

205 K, ERK, p38(MAPK), or CDK1 failed to inhibit vinblastine-induced phosphorylation of Bcl-xL or Bcl-2.

206 Vinblastine-induced spiral formation is strongly inhibit

207 disrupt polymer stability, and compete with vinblastine-induced spiral formation.

208 Vinblastine inhibited the binding of crocin to tubulin w

209 herapy consisting of dacarbazine, cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-alpha-2b) a

210 after initial diagnosis or prior exposure to vinblastine (intermediate risk) received autologous SCT

211 We provide evidence that BODIPY FL-vinblastine is a unique chemical entity different from e

212 results also suggest that the substrate drug vinblastine is released at stages that precede or follow

213 th lack the 6,7-double bond whose removal in vinblastine leads to a 100-fold drop in activity.

214 carboplatin (GC) or methotrexate/carboplatin/vinblastine (M-CAVI).

215 rgo apoptosis by the chemotherapeutic agents vinblastine, melphalan, and cis-platinum.

216 tional five cycles of VACP or five cycles of vinblastine, methotrexate with calcium leucovorin rescue

217 Vinblastine monotherapy achieved cure in patients with l

218 5 patients with intermediate risk receiving vinblastine monotherapy after the amendment experienced

219 Purpose Vinblastine monotherapy has shown promising activity and

220 rematurely, and subsequent patients received vinblastine monotherapy instead.

221 after initial diagnosis (low risk) received vinblastine monotherapy.

222 opoietic stem cell transplantation (SCT) and vinblastine monotherapy.

223 unique chemical entity different from either vinblastine or the fluorophore BODIPY FL in its function

224 H]probe 1 was inhibited by probe 1, HTI-286, vinblastine, or dolastatin 10 (another peptide antimitot

225 This effect of colchicine, vinblastine, or nocodazole was not linked to a disruptio

226 esencephalic neurons with either colchicine, vinblastine, or nocodazole, each of which disrupts micro

227 (MOPP) or procarbazine, mechlorethamine, and vinblastine (PAVe) in S studies; MOPP, PAVe, vinblastine

228 evidence that c-Jun induction in response to vinblastine plays a proapoptotic role in part via down-r

229 ts, cytoreduction with one or two courses of vinblastine plus ifosfamide plus cisplatin preceded the

230 with irreversible vincristine and reversible vinblastine, pointing to persistent cellular retention a

231 courses of vinblastine+prednisone (Arm A) or vinblastine + prednisone + methotrexate (Arm B).

232 patients received 1 to 2 six-week courses of vinblastine+prednisone (Arm A) or vinblastine + predniso

233 RO- patients received vinblastine+prednisone throughout.

234 gimens revealed 84% of patients treated with vinblastine/prednisone either did not respond or relapse

235 Toxicity was worse with the vinblastine/prednisone group as 75% had grade 3-4 neurop

236 In contrast, vinblastine/prednisone results in poor overall responses

237 to surgery, curettage, steroids, radiation, vinblastine/prednisone, 2-Chlorodeoxyadenosine (2-CdA),

238 Catastrophe induction with vinblastine prevented microtubule overgrowth and was suf

239 The P-gp inhibitors tariquidar and vinblastine prevented the efflux of rhodamine 123 (rh123

240 e randomization as alternating chlorambucil, vinblastine, procarbazine, and prednisolone (ChlVPP) wit

241 icity, and potency to reverse daunomycin and vinblastine resistances.

242 how that EM011 is potently effective against vinblastine-resistant human lymphoblastoid line CEM/VLB1

243 anosomes, and has no effect on cis-platin or vinblastine response.

244 rotubule assembly with low doses of taxol or vinblastine resulted in rapid clearance of microtubules

245 Weekly vinblastine seems to be a reasonable alternative to radi

246 ential in activity against a matched pair of vinblastine sensitive and resistant (Pgp overexpressing)

247 phoblastoid line CEM/VLB100 and its parental vinblastine-sensitive line CEM.

248 to colcemid, it did not affect paclitaxel or vinblastine sensitivity, nor did it reduce microtubule a

249 binding indicating that crocin binds at the vinblastine site on tubulin.

250 nough movement of amino acid residues at the vinblastine site to cause the latter compound to bind le

251 into this site, which was also close to the vinblastine site, resulted in enough movement of amino a

252 3342, verapamil, tetraphenylphosphonium, and vinblastine-stimulated ATPase activity.

253 Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associate

254 Trace RedOrange, BoDipy-verapamil and BoDipy-vinblastine, than any other cell in the embryo, indicati

255 Herein, we detail a synthetic vinblastine that incorporates added benign complexity (A

256 hesized a series of C20' urea derivatives of vinblastine that matched or exceeded the potency of vinb

257 approved for this disease, with methotrexate-vinblastine the only chemotherapy regimen assessed in a

258 nt tubulin assembly reaction, as occurs with vinblastine (tight spirals) or dolastatin 10 (aggregated

259 h paclitaxel, methotrexate, doxorubicin, and vinblastine to increase Ag presentation to Ag-specific T

260 ally, TTI-237 inhibited the binding of [(3)H]vinblastine to tubulin, but it caused a marked increase

261 an it inhibited the binding of colchicine or vinblastine to tubulin.

262 xoplasmic transport blockers (colchicine and vinblastine) to the sciatic nerve.

263 Vinblastine-treated cells overexpressing a Ser-62 --> Al

264 solic Bax interacted with Bcl-xL, whereas in vinblastine-treated cells, activated mitochondrial Bax d

265 e mitochondrial fraction in both control and vinblastine-treated cells, indicating that phosphorylati

266 in interactions of Bax, Bcl-2, and Bcl-xL in vinblastine-treated KB-3 cells.

267 demonstrated in mitochondrial extracts from vinblastine-treated, but not control, cells.

268 Vinblastine treatment in all cell lines examined causes

269 ating after protease inhibition or prolonged vinblastine treatment strongly resembled AVs that collec

270 Vinblastine treatment was also used to halt autophagy an

271 a, underwent multisite phosphorylation after vinblastine treatment, and was strictly monomeric under

272 disruption of microtubules by nocodazole or vinblastine treatment, as well as microtubule stabilizat

273 ules were depleted with either nocodazole or vinblastine treatment, resulting in an increase in Src2

274 oretic mobilities during the duration of the vinblastine treatment.

275 endent kinase inhibitor) gene promoter after vinblastine treatment.

276 s depleted similarly in both cell lines upon vinblastine treatment.

277 estored sensitivity to vinblastine, enhanced vinblastine uptake 3-fold, and diminished expression of

278 o determine the efficacy and safety of using vinblastine (Vbl) and methotrexate (Mtx) in children wit

279 s were refractory after at least 1 course of vinblastine (VBL) plus corticosteroid, all had liver and

280 Most notably, vinblastine (VBL) was found to induce phenotypic and fun

281 ed cytotoxicity to daunorubicin, paclitaxel, vinblastine, vincristine, and etoposide.

282 he commercially important chemotherapy drugs vinblastine, vincristine, and other synthetic derivative

283 door to new strategies for the synthesis of vinblastine, vincristine, and related anticancer agents.

284 d with VBM) or mechlorethamine, doxorubicin, vinblastine, vincristine, bleomycin, etoposide, and pred

285 ughout the pathway appear to be a feature of vinblastine/vincristine biosynthesis.

286 Vinblastine was administered once per week at a dose of

287 blunting of growing microtubule plus-ends by Vinblastine was correlated with reduced EB1 targeting.

288 (MIA)-type anticancer drugs vincristine and vinblastine, we identified a jasmonate-regulated basic h

289 Their sensitivities to Taxol and vinblastine were enhanced by hPXR ablation.

290 le key C20' urea and thiourea derivatives of vinblastine were prepared from 20'-aminovinblastine that

291 hemotherapeutics (e.g. DOX, daunorubicin, or vinblastine) were required to be Pgp substrates and also

292 This is in contrast to vinblastine which strongly stimulates large spiral polym

293 entration of the microtubule-targeting agent vinblastine, which acts to suppress microtubule dynamics

294 f c-Jun induced by the microtubule inhibitor vinblastine, which strongly induced c-Jun expression, wa

295 The newly discovered ultrapotent vinblastines, which may look highly unusual upon first i

296 ortion of patients treated with methotrexate-vinblastine who had not progressed at 6 months was 45.0%

297 uptake of calcein AM and inhibited efflux of vinblastine with IC(50)'s of approximately 2 microM in M

298 BODIPY FL-vinblastine, generated by labeling vinblastine with the fluorophore 4,4-difluoro-5,7-dimeth

299 The distribution of vinblastine within the ventricles of the brain is also d

300 rbazine, prednisone, doxorubicin, bleomycin, vinblastine) without involved field radiation therapy (I